Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Delphine Deherder
Observed names:
D Deherder,
D. Deherder,
Deherder, Delphine
Institution:
UCB Pharma (Belgium)
Observed institution:
UCB Pharma (Belgium)
ORCID:
0000-0002-7336-1988
Observed ORCID:
0000-0002-7336-1988
OpenAlex ID:
A5059312724
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
2022
·
Kenneth B. Gordon
, Richard G. Langley
, et al.
·
JAMA Dermatology
·
73
PDF
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
2023
·
Bruce Strober
, Carle Paul
, et al.
·
Journal of the American Academy of Dermatology
·
55
PDF
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
2025
·
Andrew Blauvelt
, Richard G. Langley
, et al.
·
Journal of the American Academy of Dermatology
·
27
PDF
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
2025
·
Richard B Warren
, Mark Lebwohl
, et al.
·
British Journal of Dermatology
·
23
PDF
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
2023
·
Akihiko Asahina
, Yukari Okubo
, et al.
·
Dermatology and Therapy
·
20
PDF
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension
2025
·
Christopher J. Sayed
, Brian Kirby
, et al.
·
Journal of the American Academy of Dermatology
·
11
PDF
43802 Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
2023
·
Jennifer Soung
, David Rosmarin
, et al.
·
Journal of the American Academy of Dermatology
·
2
Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT
2026
·
John R. Ingram
, Alexa B. Kimball
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study
2026
·
Lin Cai
, Xiao‐Yong Man
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
1
PDF
52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
2024
·
Kenneth B. Gordon
, Diamant Thaçi
, et al.
·
Journal of the American Academy of Dermatology
·
1
PDF
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
2022
·
Diamant Thaçi
, Ron Vender
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
2021
·
Bruce Strober
, Kim A. Papp
, et al.
·
Journal of the American Academy of Dermatology
·
1
Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”
2026
·
Emily G. Summers
, Hans Herfarth
, et al.
·
Journal of the American Academy of Dermatology
73380 Bimekizumab pharmacokinetics, safety, and efficacy in adolescents with moderate to severe plaque psoriasis: Data from the initial treatment period of the open-label BE CONNECTED phase 2 study
2026
·
Amy Paller
, Jacek C. Szepietowski
, et al.
·
Journal of the American Academy of Dermatology
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
2026
·
Diamant Thaçi
, Kenneth B. Gordon
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies
2025
·
Richard B. Warren
, Diamant Thaçi
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
62275 Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
2025
·
Andrew Blauvelt
, Saakshi Khattri
, et al.
·
Journal of the American Academy of Dermatology
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
2025
·
Yukari Okubo
, Yayoi Tada
, et al.
·
Dermatology and Therapy
PDF
Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT
2024
·
Mark Lebwohl
, Kim Papp
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
52668 Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3-year results from BE BRIGHT, a multicenter, open-label, phase 3 study
2024
·
Yukari Okubo
, Yayoi Tada
, et al.
·
Journal of the American Academy of Dermatology
PDF
52685 Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
2024
·
Diamant Thaçi
, Luis Puig
, et al.
·
Journal of the American Academy of Dermatology
PDF
Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials
2024
·
Kenneth Gordon
, Diamant Thaçi
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Ab0416 Bimekizumab Impact on Cardiovascular Inflammation Markers in Moderate to Severe Plaque Psoriasis: Results From Phase 3 Trials
2024
·
G. Kokolakis
, R.B. Warren
, et al.
·
Annals of the Rheumatic Diseases
Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials
2024
·
Mark Lebwohl
, Bruce Strober
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
43778 Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
2023
·
Bruce Strober
, Luis Puig
, et al.
·
Journal of the American Academy of Dermatology
PDF
Show more works
View as search
Works count:
33
Citation count:
216
H-index:
6
I10-index:
6
Year
Topic
Type